ClearPoint Neuro Inc.

ClearPoint Neuro Inc.

NNASDAQ:CLPT
8.30
USD
-0.18
(-2.12%)
-1.21EPS
391.35MMarket Cap
Mar 03Next Earn

Total Valuation

USD

As of September 30, 2026, ClearPoint Neuro Inc. carries a market capitalization of 391.35M, placing it among publicly traded companies globally. Its enterprise value stands at 418.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap391.35M
Enterprise Value418.86M

Important Dates

ClearPoint Neuro Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of September 30, 2026, ClearPoint Neuro Inc. has 32.05M shares outstanding.

Shares Outstanding32.05M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 8.01, and the price-to-book ratio stands at 14.35.

PS Ratio8.01
PB Ratio14.35
P/TBV Ratio53.01
P/FCF Ratio-10.97
P/OCF Ratio-11.33

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 9.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 418.86M versus a market cap of 391.35M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales9.21

Financial Position

As of September 30, 2026, ClearPoint Neuro Inc. maintains a current ratio of 6.76, meaning it holds 6.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 270.29, indicating elevated leverage, while an interest coverage ratio of -4.41 demonstrates limited ability to service its debt obligations.

Current Ratio6.76
Quick Ratio5.49
Debt / Equity270.29
Debt / EBITDA-2.72
Interest Coverage-4.41

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, ClearPoint Neuro Inc. posted a negative return on equity (ROE) of -167.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -41.75, reflecting losses generated across the asset base. The company generates approximately 264,494.19 in revenue per employee across its workforce of 172.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.15 indicates how many times ClearPoint Neuro Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-167.52
Return on Assets (ROA)-41.75
Revenue Per Employee264,494.19
Employee Count172.00
Inventory Turnover2.15

Taxes

USD

Over the twelve months ended September 30, 2026, ClearPoint Neuro Inc. recorded an income tax benefit of -30,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -36.16M and -36.13M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-30,000.00

Stock Price Statistics

USD

As of the close on November 16, 2026, ClearPoint Neuro Inc.'s stock has declined approximately 46.21% over the past 52 weeks. The 50-day moving average sits at 11.14, while the 200-day moving average is 12.68.

52-Week Price Change-46.21%
50-Day Moving Average11.14
200-Day Moving Average12.68

Income Statement

USD

Over the twelve months ended September 30, 2026, ClearPoint Neuro Inc. generated 45.49M in revenue and converted that into -36.13M in net income, yielding earnings per share of -1.21. EBITDA reached -27.14M, while operating income came in at -32.10M.

Revenue45.49M
Gross Profit27.93M
Operating Income-32.10M
Pretax Income-36.16M
Net Income-36.13M
EBITDA-27.14M
EBIT-32.10M
Earnings Per Share (EPS)-1.21

Balance Sheet

USD

As of September 30, 2026, ClearPoint Neuro Inc. holds 46.18M in cash and equivalents against 73.70M in total debt, resulting in a net debt position of 4.66M. Total book value stands at 27.27M, with working capital of 56.85M providing operational flexibility.

Cash & Cash Equivalents46.18M
Total Debt73.70M
Net Debt4.66M
Equity (Book Value)27.27M
Book Value Per Share0.85
Working Capital56.85M

Cash Flow

USD

ClearPoint Neuro Inc. produced -32.17M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.04M in capital expenditures, free cash flow totaled -33.22M - equivalent to -1.11 per share.

Operating Cash Flow-32.17M
Capital Expenditures-1.04M
Free Cash Flow-33.22M
FCF Per Share-1.11

Margins

Over the twelve months ended September 30, 2026, ClearPoint Neuro Inc. posted a gross margin of 61.39, reflecting its pricing power and cost economics. The operating margin of -70.56 and net profit margin of -79.43 provide insight into operational efficiency.

Gross Margin61.39
Operating Margin-70.56
Pretax Margin-79.50
Profit Margin-79.43
EBITDA Margin-59.66

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -9.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.42, meaning ClearPoint Neuro Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-10.42
FCF Yield-9.11

Stock Splits

ClearPoint Neuro Inc.'s most recent stock split took place on July 27, 2016 with a 40:1 split ratio.

Last Split Date7/27/2016
Split Ratio40:1

Scores

As of September 30, 2026, ClearPoint Neuro Inc. has an Altman Z-Score of -0.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.87